- Home
- MPB vs RGNX Comparison
MPB vs RGNX Comparison
Compare MPB & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MPB | RGNX |
|---|---|---|
| Founded | 1868 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 738.9M | 761.9M |
| IPO Year | 1996 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MPB | RGNX |
|---|---|---|
| Price | $32.32 | $9.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $37.00 | $29.13 |
| AVG Volume (30 Days) | 101.8K | ★ 816.8K |
| Earning Date | 04-22-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.64% | N/A |
| EPS Growth | ★ 26.64 | 23.75 |
| EPS | ★ 1.70 | N/A |
| Revenue | N/A | ★ $10,393,000.00 |
| Revenue This Year | $27.55 | $127.88 |
| Revenue Next Year | $29.71 | $42.53 |
| P/E Ratio | $19.64 | ★ N/A |
| Revenue Growth | N/A | ★ 126.48 |
| 52 Week Low | $22.50 | $5.04 |
| 52 Week High | $35.22 | $16.19 |
Technical Indicators
Market Signals| Indicator | MPB | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 43.13 | 40.54 |
| Support Level | $30.69 | $7.67 |
| Resistance Level | $35.01 | $9.28 |
| Average True Range (ATR) | 0.99 | 0.60 |
| MACD | -0.21 | 0.16 |
| Stochastic Oscillator | 6.76 | 45.85 |
Price Performance
Historical ComparisonAbout MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.